Cargando…

Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort

BACKGROUND: We aimed to estimate the seroprevalence of SARS-CoV-2 infection in France and to identify the populations most exposed during the first epidemic wave. METHODS: Random selection of individuals aged 15 years or over, from the national tax register (96% coverage). Socio-economic data, migra...

Descripción completa

Detalles Bibliográficos
Autores principales: Warszawski, Josiane, Beaumont, Anne-Lise, Seng, Rémonie, de Lamballerie, Xavier, Rahib, Delphine, Lydié, Nathalie, Slama, Rémy, Durrleman, Sylvain, Raynaud, Philippe, Sillard, Patrick, Beck, François, Meyer, Laurence, Bajos, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743062/
https://www.ncbi.nlm.nih.gov/pubmed/35000580
http://dx.doi.org/10.1186/s12879-021-06973-0
_version_ 1784629828308172800
author Warszawski, Josiane
Beaumont, Anne-Lise
Seng, Rémonie
de Lamballerie, Xavier
Rahib, Delphine
Lydié, Nathalie
Slama, Rémy
Durrleman, Sylvain
Raynaud, Philippe
Sillard, Patrick
Beck, François
Meyer, Laurence
Bajos, Nathalie
author_facet Warszawski, Josiane
Beaumont, Anne-Lise
Seng, Rémonie
de Lamballerie, Xavier
Rahib, Delphine
Lydié, Nathalie
Slama, Rémy
Durrleman, Sylvain
Raynaud, Philippe
Sillard, Patrick
Beck, François
Meyer, Laurence
Bajos, Nathalie
author_sort Warszawski, Josiane
collection PubMed
description BACKGROUND: We aimed to estimate the seroprevalence of SARS-CoV-2 infection in France and to identify the populations most exposed during the first epidemic wave. METHODS: Random selection of individuals aged 15 years or over, from the national tax register (96% coverage). Socio-economic data, migration history, and living conditions were collected via self-computer-assisted-web or computer-assisted-telephone interviews. Home self-sampling was performed for a random subsample, to detect IgG antibodies against spike protein (Euroimmun), and neutralizing antibodies with in-house assays, in dried blood spots (DBS). RESULTS: The questionnaire was completed by 134,391 participants from May 2nd to June 2st, 2020, including 17,441 eligible for DBS 12,114 of whom were tested. ELISA-S seroprevalence was 4.5% [95% CI 3.9–5.0] overall, reaching up to 10% in the two most affected areas. High-density residences, larger household size, having reported a suspected COVID-19 case in the household, working in healthcare, being of intermediate age and non-daily tobacco smoking were independently associated with seropositivity, whereas living with children or adolescents did not remain associated after adjustment for household size. Adjustment for both residential density and household size accounted for much of the higher seroprevalence in immigrants born outside Europe, twice that in French natives in univariate analysis. CONCLUSION: The EPICOV cohort is one of the largest national representative population-based seroprevalence surveys for COVID-19. It shows the major role of contextual living conditions in the initial spread of COVID-19 in France, during which the availability of masks and virological tests was limited. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06973-0.
format Online
Article
Text
id pubmed-8743062
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87430622022-01-10 Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort Warszawski, Josiane Beaumont, Anne-Lise Seng, Rémonie de Lamballerie, Xavier Rahib, Delphine Lydié, Nathalie Slama, Rémy Durrleman, Sylvain Raynaud, Philippe Sillard, Patrick Beck, François Meyer, Laurence Bajos, Nathalie BMC Infect Dis Research BACKGROUND: We aimed to estimate the seroprevalence of SARS-CoV-2 infection in France and to identify the populations most exposed during the first epidemic wave. METHODS: Random selection of individuals aged 15 years or over, from the national tax register (96% coverage). Socio-economic data, migration history, and living conditions were collected via self-computer-assisted-web or computer-assisted-telephone interviews. Home self-sampling was performed for a random subsample, to detect IgG antibodies against spike protein (Euroimmun), and neutralizing antibodies with in-house assays, in dried blood spots (DBS). RESULTS: The questionnaire was completed by 134,391 participants from May 2nd to June 2st, 2020, including 17,441 eligible for DBS 12,114 of whom were tested. ELISA-S seroprevalence was 4.5% [95% CI 3.9–5.0] overall, reaching up to 10% in the two most affected areas. High-density residences, larger household size, having reported a suspected COVID-19 case in the household, working in healthcare, being of intermediate age and non-daily tobacco smoking were independently associated with seropositivity, whereas living with children or adolescents did not remain associated after adjustment for household size. Adjustment for both residential density and household size accounted for much of the higher seroprevalence in immigrants born outside Europe, twice that in French natives in univariate analysis. CONCLUSION: The EPICOV cohort is one of the largest national representative population-based seroprevalence surveys for COVID-19. It shows the major role of contextual living conditions in the initial spread of COVID-19 in France, during which the availability of masks and virological tests was limited. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06973-0. BioMed Central 2022-01-09 /pmc/articles/PMC8743062/ /pubmed/35000580 http://dx.doi.org/10.1186/s12879-021-06973-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Warszawski, Josiane
Beaumont, Anne-Lise
Seng, Rémonie
de Lamballerie, Xavier
Rahib, Delphine
Lydié, Nathalie
Slama, Rémy
Durrleman, Sylvain
Raynaud, Philippe
Sillard, Patrick
Beck, François
Meyer, Laurence
Bajos, Nathalie
Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
title Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
title_full Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
title_fullStr Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
title_full_unstemmed Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
title_short Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
title_sort prevalence of sars-cov-2 antibodies and living conditions: the french national random population-based epicov cohort
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743062/
https://www.ncbi.nlm.nih.gov/pubmed/35000580
http://dx.doi.org/10.1186/s12879-021-06973-0
work_keys_str_mv AT warszawskijosiane prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT beaumontannelise prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT sengremonie prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT delamballeriexavier prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT rahibdelphine prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT lydienathalie prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT slamaremy prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT durrlemansylvain prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT raynaudphilippe prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT sillardpatrick prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT beckfrancois prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT meyerlaurence prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT bajosnathalie prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort
AT prevalenceofsarscov2antibodiesandlivingconditionsthefrenchnationalrandompopulationbasedepicovcohort